Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 16, 2023, Senti Biosciences, Inc. (the "Company") held its virtual 2023
Annual Meeting of Stockholders (the "Annual Meeting"). The proposals set forth
below were submitted to the stockholders at the Annual Meeting and are further
described in the Company's proxy statement.
At the Annual Meeting, the Company's stockholders: (i) elected each of the three
Class I directors, Timothy Lu, M.D., Ph.D., Edward Mathers, and Omid Farokhzad,
M.D., to the Company's board of directors to serve until the 2026 annual meeting
of stockholders and until their successor has been duly elected and qualified,
or until their earlier death, resignation or removal, and (ii) ratified the
appointment of KPMG LLP as the Company's independent registered public
accounting firm for the fiscal year ending December 31, 2023.
Represented in person or by proxy at the Annual Meeting were 34,465,609 shares
of the Company's common stock, out of 44,168,034 shares entitled to vote at the
Annual Meeting, or 78.0% of the total number of shares outstanding as of the
record date. The results of the matters submitted to a stockholder vote at the
Annual Meeting were as follows.
1. Election of directors:
Name For Withheld Broker Non-Votes
Timothy Lu, M.D., Ph.D. 32,295,728 81,697 2,088,184
Edward Mathers 22,511,863 9,865,562 2,088,184
Omid Farokhzad, M.D. 26,184,748 6,192,677 2,088,184
2. Ratification of the appointment of KPMG LLP as the independent registered
public accounting firm for the fiscal year ending December 31, 2023:
For Against Abstain
34,350,453 60,890 54,266
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses